Top

Published in:

01-06-2011 | Original Article

A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC

Authors: Athanasios G. Pallis, Vassilis Chandrinos, Georgia Pavlakou, Nikolaos Xenidis, Ioannis Varthalitis, Nikolaos Vardakis, Lambros Vamvakas, Emmanouel Kontopodis, Maria Rovithi, Vassilis Georgoulias

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2011

Abstract

The purpose of the present study was to determine the maximum-tolerated doses (MTDs) and the dose-limiting toxicities of a metronomic administration of oral vinorelbine and cisplatin in patients with advanced/metastatic NSCLC. Twenty-six patients with advanced/metastatic NSCLC were enrolled. Escalating doses of vinorelbine (40–70 mg p.o./trice per week) and cisplatin (70–85 mg/m² intravenous infusion) were administered on day 1 every 3 weeks. ΜΤDs were reached at 60 mg thrice/week p.o. for vinorelbine and 85 mg/m² for cisplatin. Grade 4 neutropenia, febrile neutropenia and grade 4 diarrhea were the dose-limiting events during the first cycle of chemotherapy. The most common grade III-IV hematologic toxicity was neutropenia occurring in seven (27%) patients, while non-hematological toxicities were relatively infrequent and mostly of grade I or II. Objective responses were observed in 20.8% of patients with measurable disease. The regimen of metronomic administration and cisplatin is feasible and active in patients with NSCLC.

Goa KL, Faulds D (1994) Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging 5:200–234PubMedCrossRef

Potier P (1989) The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol 16:2–4PubMed

Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12:1643–1649PubMedCrossRef

Gralla RJ, Gatzemeier U, Gebbia V, Huber R, O’Brien M, Puozzo C (2007) Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management. Drugs 67:1403–1410PubMedCrossRef

Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyk K, Krzakowski M, Zatloukal P, Lemarie E, Hartmann W, Novakova L, O’Brien M, Depierr A (2001) A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 12:1375–1381PubMedCrossRef

Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045–1047PubMedCrossRef

Kerbel RS, Klement G, Pritchard KI, Kamen B (2002) Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 13:12–15PubMedCrossRef

Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436PubMedCrossRef

Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, Marselos M, Pavlidis N (2009) Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 15:6454–6461PubMedCrossRef

10.

(1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small cell lung cancer collaborative group. BMJ 311:899–909

11.

Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2009) American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27(36):6251–6266

12.

Jassem J, Kosmidis P, Ramlau R, Zarogoulidis K, Novakova L, Breton J, Etienne PL, Seebacher C, Grivaux M, Ojala A, Aubert D, Lefresne F (2003) Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann Oncol 14:1634–1639PubMedCrossRef

13.

Chen YM, Yu CJ, Yang CH, Perng RP, Tsai CM, Shih JF, Cheng AL, Lefresne F, Barbier M, Pouget JC, Yang PC (2007) A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma. Lung Cancer 56:89–95PubMedCrossRef

14.

Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, La PM, Sciandivasci A, Paolelli L, Pascucci A, Rossi M, Di BM, Giorgi G, Gotti G, Francini G (2006) A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 16:133–140PubMed

15.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef

16.

ICH Efficacy Guidelines.E6(R1) (2009) Good clinical practice: consolidated guideline. http://www.ich.org/cache/compo/475-272-1.html

17.

Cancer Therapy Evaluation Program (1998) Common toxicity criteria. Version 2.0. DCTD, NCI, NIH, DHHS

18.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. JNCI Cancer Spectr 92:205–216

19.

Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62:6938–6943PubMed

20.

Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K (1989) Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 32:1065–1073PubMedCrossRef

21.

Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V (2003) Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 63:8408–8413PubMed

22.

Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R (2003) Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 98:1643–1648PubMedCrossRef

23.

Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nole F, Viale G, Goldhirsch A (2006) Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17:232–238PubMedCrossRef

24.

Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, Dogliotti L, Berruti A (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24:3623–3628PubMedCrossRef

25.

Schwartz EL (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15:2594–2601PubMedCrossRef

26.

Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C, Giavazzi R, Hill BT, Taraboletti G (2006) Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer 42:2821–2832PubMedCrossRef

27.

Douillard JY, Rosell R, De LM, Carpagnano F, Ramlau R, Gonzales-Larriba JL, Grodzki T, Pereira JR, Le GA, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7:719–727PubMedCrossRef

28.

Arriagada R, Bergman B, Dunant A, Le CT, Pignon JP, Vansteenkiste J (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360PubMedCrossRef

29.

Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937–2945PubMedCrossRef

30.

Pirker R, Pereira JR, Szczesna A, Von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O’Byrne K, De Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525–1531PubMedCrossRef

31.

Tan EH, Rolski J, Grodzki T, Schneider CP, Gatzemeier U, Zatloukal P, Aitini E, Carteni G, Riska H, Tsai YH, Abratt R (2009) Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 20:1249–1256PubMedCrossRef

Title: A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC
Authors: Athanasios G. Pallis
Vassilis Chandrinos
Georgia Pavlakou
Nikolaos Xenidis
Ioannis Varthalitis
Nikolaos Vardakis
Lambros Vamvakas
Emmanouel Kontopodis
Maria Rovithi
Vassilis Georgoulias
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1415-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2011

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis

Estimating the correct way of calculating the carboplatin dose

Prospectives and limitations by a novel algorithm

Erratum to: Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer